Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

154.67USD
20 Jan 2017
Change (% chg)

$0.87 (+0.57%)
Prev Close
$153.80
Open
$154.71
Day's High
$155.35
Day's Low
$153.82
Volume
3,067,152
Avg. Vol
3,748,726
52-wk High
$176.85
52-wk Low
$133.64

Latest Key Developments (Source: Significant Developments)

Amgen comments on Delaware court's ruling on PCSK9 patent litigation
Monday, 9 Jan 2017 08:04pm EST 

Amgen Inc : Amgen statement on January 9, 2017, U.S. District court decision . Amgen Inc - U.S. District court of Delaware denied Sanofi and Regeneron's motion to stay injunction pending appeal in ongoing PCSK9 patent litigation .Amgen Inc says by ruling, court has extended time before injunction will be imposed by 15 days (from 30 days to 45 days).  Full Article

Amgen comments on Delaware court's ruling on PCSK9 patent litigation
Monday, 9 Jan 2017 06:21pm EST 

Amgen Inc : Amgen statement on January 9, 2017, U.S. District court decision . Amgen Inc - U.S. District court of Delaware denied Sanofi and Regeneron's motion to stay injunction pending appeal in ongoing PCSK9 patent litigation .Amgen Inc says by ruling, court has extended time before injunction will be imposed by 15 days (from 30 days to 45 days).  Full Article

Amgen and Davita enter into new sourcing and supply agreement
Monday, 9 Jan 2017 06:00am EST 

Amgen Inc : Amgen and Davita enter into new sourcing and supply agreement . New agreement will replace sourcing and supply agreement dated Nov. 15, 2011, between Amgen and Davita . Amgen and Davita enter into new sourcing and supply agreement . Amgen will supply davita with Epogen and Aranesp in amounts necessary to meet specified percentage of Davita's and its affiliates' needs .Specified percentage varies during term of new agreement from Jan. 6, 2017, through Dec. 31, 2022, but in each year is at least 90 percent.  Full Article

Court grants permanent injunction for infringement of Amgen's Repatha patents
Thursday, 5 Jan 2017 09:34pm EST 

Amgen Inc : Court grants permanent injunction for infringement of Amgen's repatha patents .Says injunction will not take effect immediately as court has delayed its imposition for 30 days.  Full Article

Amgen announces 15 pct increase in Q1 2017 dividend
Tuesday, 20 Dec 2016 04:20pm EST 

Amgen Inc : Amgen announces 15 percent increase in 2017 first quarter dividend .Sets quarterly dividend of $1.15per share.  Full Article

Amgen Astellas and Astellas announce submission of application for investigational osteoporosis medication romosozumab in Japan
Tuesday, 20 Dec 2016 12:17am EST 

Astellas Pharma Inc <4503.T>: Says Amgen Astellas BioPharma K.K. and Astellas Pharma Inc announced that Amgen Astellas submitted an application seeking marketing approval of romosozumab (AMG785) for the treatment of osteoporosis for those at high risk of fracture for review to the Ministry of Health, Labour and Welfare in Japan .Says Amgen Astellas and Astellas are co-developing romosozumab in Japan.  Full Article

UCB and Amgen seek marketing approval of romosozumab in Japan
Monday, 19 Dec 2016 07:00pm EST 

UCB SA :Says Amgen and UCB announce submission of application for investigational osteoporosis medication romosozumab in Japan.  Full Article

Cytokinetics starts phase 3 clinical trial of omecamtiv mecarbil
Thursday, 1 Dec 2016 07:30am EST 

Cytokinetics Inc: Cytokinetics announces start of galactic-hf, a phase 3 clinical trial of omecamtiv mecarbil . Coincident with start of trial, Amgen will make a $26.7 million milestone payment to CytoKinetics .Cytokinetics - galactic-hf will be conducted under a special protocol assessment (spa) with U.S. FDA.  Full Article

Janssen reports clinical trial collaboration and supply agreement with Amgen to evaluate Daratumumab in combination with Carfilzomib
Thursday, 10 Nov 2016 08:34am EST 

Amgen Inc : Janssen Biotech - financial terms have not been disclosed .Janssen announces clinical trial collaboration and supply agreement with Amgen to evaluate Daratumumab (darzalex®) in combination with Carfilzomib (kyprolis®).  Full Article

Amgen Inc Q3 Non-GAAP EPS $3.02
Thursday, 27 Oct 2016 04:01pm EDT 

Amgen Inc : Q3 GAAP earnings per share $2.68; Q3 Non-GAAP earnings per share $3.02; Q3 revenue $5.8 billion, up 2 percent . 2016 revenue guidance increased to $22.6 billion to $22.8 billion; 2016 GAAP EPS guidance increased to $9.94 to $10.11, Non-GAAP EPS guidance increased to $11.40 to $11.55 . Q3 earnings per share view $2.79, revenue view $5.73 billion -- Thomson Reuters I/B/E/S . sees 2016 capital expenditures to be approximately $700 million .FY 2016 earnings per share view $11.36, revenue view $22.77 billion -- Thomson Reuters I/B/E/S.  Full Article

Trump's health pick set to defend investments at U.S. Senate hearing

WASHINGTON, Jan 18 President-elect Donald Trump's nominee for health secretary was expected to face hard questions from a U.S. Senate panel on Wednesday about his personal stock investments and proposals to dismantle Obamacare.